Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency

Michael A Campos, Saleh Alazemi, Guoyan Zhang, Adam Wanner, Robert A. Sandhaus

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Disease management programs improve outcomes in subjects with chronic obstructive pulmonary disease (COPD), but their effect in subjects with alpha-1 antitrypsin deficiency (AATD) has not been evaluated. To assess the impact of a disease management program, applicable to subjects with AATD-associated COPD throughout the United States, on exacerbations, healthcare resource utilization and health-related quality of life (HRQoL). The Alpha-1 Disease Management and Prevention Program (ADMAPP) consisted of comprehensive written educational patient-directed material for self-study and treatment plans. Program reinforcement was performed through monthly phone calls by specialized coordinators. Outcomes were collected prospectively for 12 months before, and 12 months after enrollment into the program. Exacerbations and healthcare resource utilization were recorded monthly. HRQoL was measured with the St George's Respiratory Questionnaire (SGRQ) every 6 months and the Short Form-36 (SF-36) every 12 months. A total of 878 subjects completed the 2-year study. During the intervention year, there was a significant increase in the use of long-acting bronchodilators, better compliance with oxygen therapy, and more use of steroid courses during exacerbations. Total exacerbation rates, unscheduled physician visits and emergency room visits significantly decreased. There was also a statistically significant slowing in the deterioration of the SGRQ's activity domain, while total SGRQ scores remained stable during the study. Significant improvements were observed in some of the SF-36 domains, particularly in the general health domain. The ADMAPP improved health outcomes in subjects with AATD-associated COPD.

Original languageEnglish
Pages (from-to)31-40
Number of pages10
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume6
Issue number1
DOIs
StatePublished - Feb 28 2009

Fingerprint

alpha 1-Antitrypsin Deficiency
Disease Management
Chronic Obstructive Pulmonary Disease
Quality of Life
Delivery of Health Care
Bronchodilator Agents
Health
Hospital Emergency Service
Steroids
Oxygen
Physicians
Autosomal Recessive alpha-1-Antitrypsin Deficiency
Therapeutics
Surveys and Questionnaires

Keywords

  • Alpha-1 antitrypsin deficiency
  • Chronic obstructive pulmonary disease
  • Disease management
  • Quality of life

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. / Campos, Michael A; Alazemi, Saleh; Zhang, Guoyan; Wanner, Adam; Sandhaus, Robert A.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 6, No. 1, 28.02.2009, p. 31-40.

Research output: Contribution to journalArticle

@article{fa6fd4ec03ad45d0a3696d0fa8416aeb,
title = "Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency",
abstract = "Disease management programs improve outcomes in subjects with chronic obstructive pulmonary disease (COPD), but their effect in subjects with alpha-1 antitrypsin deficiency (AATD) has not been evaluated. To assess the impact of a disease management program, applicable to subjects with AATD-associated COPD throughout the United States, on exacerbations, healthcare resource utilization and health-related quality of life (HRQoL). The Alpha-1 Disease Management and Prevention Program (ADMAPP) consisted of comprehensive written educational patient-directed material for self-study and treatment plans. Program reinforcement was performed through monthly phone calls by specialized coordinators. Outcomes were collected prospectively for 12 months before, and 12 months after enrollment into the program. Exacerbations and healthcare resource utilization were recorded monthly. HRQoL was measured with the St George's Respiratory Questionnaire (SGRQ) every 6 months and the Short Form-36 (SF-36) every 12 months. A total of 878 subjects completed the 2-year study. During the intervention year, there was a significant increase in the use of long-acting bronchodilators, better compliance with oxygen therapy, and more use of steroid courses during exacerbations. Total exacerbation rates, unscheduled physician visits and emergency room visits significantly decreased. There was also a statistically significant slowing in the deterioration of the SGRQ's activity domain, while total SGRQ scores remained stable during the study. Significant improvements were observed in some of the SF-36 domains, particularly in the general health domain. The ADMAPP improved health outcomes in subjects with AATD-associated COPD.",
keywords = "Alpha-1 antitrypsin deficiency, Chronic obstructive pulmonary disease, Disease management, Quality of life",
author = "Campos, {Michael A} and Saleh Alazemi and Guoyan Zhang and Adam Wanner and Sandhaus, {Robert A.}",
year = "2009",
month = "2",
day = "28",
doi = "10.1080/15412550802607410",
language = "English",
volume = "6",
pages = "31--40",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency

AU - Campos, Michael A

AU - Alazemi, Saleh

AU - Zhang, Guoyan

AU - Wanner, Adam

AU - Sandhaus, Robert A.

PY - 2009/2/28

Y1 - 2009/2/28

N2 - Disease management programs improve outcomes in subjects with chronic obstructive pulmonary disease (COPD), but their effect in subjects with alpha-1 antitrypsin deficiency (AATD) has not been evaluated. To assess the impact of a disease management program, applicable to subjects with AATD-associated COPD throughout the United States, on exacerbations, healthcare resource utilization and health-related quality of life (HRQoL). The Alpha-1 Disease Management and Prevention Program (ADMAPP) consisted of comprehensive written educational patient-directed material for self-study and treatment plans. Program reinforcement was performed through monthly phone calls by specialized coordinators. Outcomes were collected prospectively for 12 months before, and 12 months after enrollment into the program. Exacerbations and healthcare resource utilization were recorded monthly. HRQoL was measured with the St George's Respiratory Questionnaire (SGRQ) every 6 months and the Short Form-36 (SF-36) every 12 months. A total of 878 subjects completed the 2-year study. During the intervention year, there was a significant increase in the use of long-acting bronchodilators, better compliance with oxygen therapy, and more use of steroid courses during exacerbations. Total exacerbation rates, unscheduled physician visits and emergency room visits significantly decreased. There was also a statistically significant slowing in the deterioration of the SGRQ's activity domain, while total SGRQ scores remained stable during the study. Significant improvements were observed in some of the SF-36 domains, particularly in the general health domain. The ADMAPP improved health outcomes in subjects with AATD-associated COPD.

AB - Disease management programs improve outcomes in subjects with chronic obstructive pulmonary disease (COPD), but their effect in subjects with alpha-1 antitrypsin deficiency (AATD) has not been evaluated. To assess the impact of a disease management program, applicable to subjects with AATD-associated COPD throughout the United States, on exacerbations, healthcare resource utilization and health-related quality of life (HRQoL). The Alpha-1 Disease Management and Prevention Program (ADMAPP) consisted of comprehensive written educational patient-directed material for self-study and treatment plans. Program reinforcement was performed through monthly phone calls by specialized coordinators. Outcomes were collected prospectively for 12 months before, and 12 months after enrollment into the program. Exacerbations and healthcare resource utilization were recorded monthly. HRQoL was measured with the St George's Respiratory Questionnaire (SGRQ) every 6 months and the Short Form-36 (SF-36) every 12 months. A total of 878 subjects completed the 2-year study. During the intervention year, there was a significant increase in the use of long-acting bronchodilators, better compliance with oxygen therapy, and more use of steroid courses during exacerbations. Total exacerbation rates, unscheduled physician visits and emergency room visits significantly decreased. There was also a statistically significant slowing in the deterioration of the SGRQ's activity domain, while total SGRQ scores remained stable during the study. Significant improvements were observed in some of the SF-36 domains, particularly in the general health domain. The ADMAPP improved health outcomes in subjects with AATD-associated COPD.

KW - Alpha-1 antitrypsin deficiency

KW - Chronic obstructive pulmonary disease

KW - Disease management

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=61649086692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61649086692&partnerID=8YFLogxK

U2 - 10.1080/15412550802607410

DO - 10.1080/15412550802607410

M3 - Article

C2 - 19229706

AN - SCOPUS:61649086692

VL - 6

SP - 31

EP - 40

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - 1

ER -